NewAmsterdam Pharma (NAMS) Non-Current Deffered Revenue (2022 - 2024)
NewAmsterdam Pharma (NAMS) posted Non-Current Deffered Revenue of $222000.0 for Q2 2024, down 50.0% sequentially from $444000.0 in Q1 2024.
NewAmsterdam Pharma (NAMS) Non-Current Deffered Revenue (2022 - 2024) Analysis & Trends
NewAmsterdam Pharma has reported Non-Current Deffered Revenue for 3 years, with the latest figure at $222000.0 in Q2 2024.
- Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $222000.0 in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $222000.0 (changed N/A YoY) and the FY2023 annual result came in at $1.0 million, down 78.74% from the prior year.
- Non-Current Deffered Revenue retreated to $222000.0 in Q2 2024 per NAMS's latest filing, from $444000.0 in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $4.8 million in Q4 2022 and troughed at $222000.0 in Q2 2024.
- A 3-year average of $1.6 million and a median of $731500.0 in 2023 frame the typical range for Non-Current Deffered Revenue.
- The widest YoY moves for Non-Current Deffered Revenue: up 78.74% in 2023, down 78.74% in 2023.
- Over 3 years, Non-Current Deffered Revenue stood at $4.8 million in 2022, then plunged by 78.74% to $1.0 million in 2023, then tumbled by 78.21% to $222000.0 in 2024.
- According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $222000.0, $444000.0, and $1.0 million for Q2 2024, Q1 2024, and Q4 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | NewAmsterdam Pharma | 3.17 Bn | 3.17 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 222,000.00 |
| Mar 31, 2024 | 444,000.00 |
| Dec 31, 2023 | 1.02 Mn |
| Dec 31, 2022 | 4.79 Mn |